Skip to main content

Table 1 Number of patients and demographic data

From: Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective

 

Etanercept

Adalimumab

Infliximab

Patients

233

201

121

Mean age (standard deviation)

54 (15,20)*

51 (15,12)**

41 (12,16)

Female, %

63***

59

51

  1. * p < 0.05 compared with adalimumab and infliximab.
  2. ** p < 0.05 compared with infliximab.
  3. *** p < 0.05 compared with infliximab.
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us